Pyc Therapeutics
Clinical trials sponsored by Pyc Therapeutics, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Scientists track vision loss in rare genetic eye disease to pave way for future treatments Results expected Sep 2026 (estimated)
-
New hope for kidney disease: first human trial of PYC-003 begins
Disease control Recruiting nowThis study is the first time a new drug called PYC-003 is being tested in humans. It is for people with a genetic kidney disease that causes cysts to grow and damage the kidneys. The trial will first test the drug in healthy volunteers to check safety, then in patients with the d…
Phase 1 • Sponsor: PYC Therapeutics • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
New eye drug hopes to slow inherited blindness
Disease control Recruiting nowThis early-stage study tests a new medicine called PYC-001, given as an injection into the eye, for people with a rare genetic eye disease (autosomal dominant optic atrophy) caused by a change in the OPA1 gene. The main goal is to check the safety of different doses and schedules…
Phase 1/2 • Sponsor: PYC Therapeutics • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC